
Sign up to save your podcasts
Or


Dr. Anna Wolska from the Lupus Foundation of America interviews Dr. Ian Bruce, from the University of Manchester in the UK. Dr Bruce discusses the time to onset of clinical response to Anifrolumab in patients with Systemic Lupus Erythematosus. The episode delves into pooled data from two significant Phase III trials, TULIP-1 and TULIP-2, offering listeners a deep understanding of the effectiveness and timeline of Anifrolumab treatment.
Read the article: http://dx.doi.org/10.1136/lupus-2022-000761
By BMJ Group4
1515 ratings
Dr. Anna Wolska from the Lupus Foundation of America interviews Dr. Ian Bruce, from the University of Manchester in the UK. Dr Bruce discusses the time to onset of clinical response to Anifrolumab in patients with Systemic Lupus Erythematosus. The episode delves into pooled data from two significant Phase III trials, TULIP-1 and TULIP-2, offering listeners a deep understanding of the effectiveness and timeline of Anifrolumab treatment.
Read the article: http://dx.doi.org/10.1136/lupus-2022-000761

497 Listeners

36 Listeners

48 Listeners

5 Listeners

7 Listeners

6 Listeners

3 Listeners

2 Listeners

3 Listeners

9 Listeners

40 Listeners

14 Listeners

1 Listeners

48 Listeners

0 Listeners

6 Listeners

28,586 Listeners

500 Listeners

131 Listeners

3 Listeners

20 Listeners

16,920 Listeners

33,452 Listeners

9,241 Listeners

23 Listeners

27,558 Listeners

31 Listeners

4 Listeners

19,831 Listeners

2 Listeners

46 Listeners

0 Listeners

1,621 Listeners

681 Listeners